Agios Pharmaceuticals, Inc. (AGIO) Stock

Agios Pharmaceuticals, Inc. (AGIO) is a Healthcare stock trading at $34.16 (as of 2026-06-18), with a market capitalization of $1.65B and a trailing P/E of -4.7. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Valuation — source: SEC EDGAR (first-party)
Price	$34.16
Market Cap	$1.65B
P/E Ratio	-4.7
EV / EBITDA	-4.1
Price / Book	1.83
Price / Sales	30.76
DCF Value (model)	$-108.10
DCF Upside vs Price	-416.5%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$54.03M
Net Margin	-764.0%
Return on Equity	-38.1%
Current Ratio	14.19
Revenue Growth (YoY)	48.0%
EPS Growth (YoY)	-160.0%
FCF Growth (YoY)	-3.6%

Financial Health — source: SEC EDGAR
Altman Z-Score	10.19 (safe)

Valuation vs Sector & Industry
Stock P/E	-4.7
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-122.4%
vs Industry	-127.3%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BlackRock, Inc. ($194.69M)
Institutional Holders Tracked	10
Congressional Trades (recent)	3

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Brian Goff
Employees	486
Country	US
IPO Date	2013-07-24

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.